Insider Selling: Glaukos (NYSE:GKOS) Director Sells $632,500.00 in Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 2,500 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the transaction, the director owned 37,406 shares in the company, valued at $9,463,718. This represents a 6.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Glaukos Stock Up 1.8%

Shares of Glaukos stock opened at $223.96 on Friday. The business has a 50-day moving average of $178.24 and a 200-day moving average of $144.09. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09. The company has a market capitalization of $13.26 billion, a PE ratio of -76.18 and a beta of 0.68. Glaukos Corporation has a 1-year low of $80.90 and a 1-year high of $255.18.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.57. The business had revenue of $211.03 million for the quarter, compared to analysts’ expectations of $168.04 million. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The company’s revenue was up 58.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. As a group, equities analysts forecast that Glaukos Corporation will post 0.50 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of recent analyst reports. Mizuho set a $225.00 price target on shares of Glaukos in a research report on Thursday, October 29th. BTIG Research upped their price target on shares of Glaukos from $205.00 to $234.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Stifel Nicolaus increased their price objective on shares of Glaukos from $190.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Jefferies Financial Group increased their price objective on shares of Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. Finally, Wells Fargo & Company raised their price objective on shares of Glaukos from $178.00 to $226.00 and gave the stock an “overweight” rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.71.

Institutional Trading of Glaukos

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Glaukos during the 2nd quarter valued at approximately $1,333,318,000. Jupiter Topco LLC acquired a new stake in Glaukos in the second quarter worth $679,614,000. Janus Henderson Group PLC increased its position in Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after buying an additional 2,329,608 shares during the period. Primecap Management Co. CA acquired a new stake in Glaukos in the second quarter worth $424,969,000. Finally, William Blair Investment Management LLC bought a new stake in Glaukos in the second quarter valued at $92,476,000. Institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period.

The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.